Patricia Zilliox, an expert in eye diseases, has become the chief executive officer of Eyevensys SAS, a France-based company developing non-viral gene therapies for ophthalmic diseases. She assumed the executive role in December 2017 after serving on the company’s board of directors. Previously, Dr Zilliox was chief drug development officer at a unit of the Foundation Fighting Blindness in the US. Before that, she managed clinical development at Alcon Laboratories, now part of Novartis.
Dr Zilliox received both a pharmacy degree and a PhD from the University Louis Pasteur in Strasbourg France.
Eyevensys announced the appointment on 12 December 2017.
Copyright 2018 Evernow Publishing Ltd